Centre Proposes Immediate Suspension of Drug Manufacturing Licences for Substandard Medicines in India

The Centre has proposed stricter drug regulations, allowing immediate suspension of manufacturing licences for substandard medicines to improve pharmaceutical quality, strengthen patient safety and ensure accountability.

Centre Proposes Immediate Suspension of Manufacturing Licences for Substandard Drugs

The Union Ministry of Health and Family Welfare has proposed significant changes to the Drugs Rules, 1945, to strengthen India's pharmaceutical regulatory framework. Under the proposed amendments, authorities will be empowered to immediately suspend manufacturing licences for medicines found to be Not of Standard Quality (NSQ) on specified critical quality parameters.

The proposed changes aim to prevent the production and distribution of substandard medicines and ensure faster regulatory action when serious quality issues are identified.

The initiative is expected to strengthen drug quality monitoring, improve accountability among pharmaceutical manufacturers and protect patients from potentially unsafe or ineffective medicines.

Centre Proposes Immediate Suspension of Drug Manufacturing Licences

Under the existing regulatory framework, suspending or cancelling a drug manufacturing licence involves a prescribed procedure, which generally includes issuing a show-cause notice to the manufacturer.

According to the Health Ministry, this process can create delays between identifying a quality-related problem and taking regulatory action. During this period, medicines that fail to meet prescribed standards could potentially remain in circulation.

To address this concern, the government has proposed giving the Central Licensing Approving Authority and the concerned State Licensing Authority the power to immediately suspend manufacturing licences when a Government Analyst's report confirms that a drug is NSQ on specified critical parameters.

Which Drug Quality Parameters Will Be Covered?

The proposed immediate suspension mechanism will apply to failures involving five important quality parameters:

• Assay: Measures whether a medicine contains the required amount of its active pharmaceutical ingredient.

• Dissolution: Evaluates how effectively the drug releases its active ingredient.

• Related substances: Identifies substances associated with the drug's manufacturing process or degradation.

• Impurities: Checks for unwanted substances that could affect medicine quality and safety.

• Sterility: Determines whether medicines required to be sterile are free from viable microorganisms.

These parameters are essential for evaluating the quality, safety and effectiveness of pharmaceutical products.

Manufacturers Must Complete Root Cause Analysis and CAPA

The proposed amendments also introduce stricter requirements for manufacturers seeking restoration of suspended licences.

Companies will not automatically regain permission to manufacture medicines after a suspension. They will first need to identify the reasons behind the quality failure and demonstrate that appropriate corrective measures have been implemented.

Root Cause Analysis Becomes Mandatory

Manufacturers will be required to conduct a Root Cause Analysis to determine the underlying reasons responsible for the failure of a medicine to meet prescribed quality standards.

This process will help identify weaknesses in manufacturing procedures, quality control systems and other operational activities.

Corrective and Preventive Action (CAPA)

Companies will also need to implement Corrective and Preventive Action (CAPA) measures.

These measures are intended to resolve existing quality problems and prevent similar failures from occurring again.

The suspension will remain effective until the concerned Licensing Authority examines the corrective steps and confirms that the required quality safeguards have been established.

Government Proposes Stronger Reporting and Regulatory Coordination

Apart from introducing immediate suspension powers, the Ministry has proposed changes to Form 13 under the Drugs Rules, 1945.

Form 13 contains the Government Analyst's test report and plays an important role in communicating the quality status of pharmaceutical products.

Under the proposed amendments, reports declaring medicines as Not of Standard Quality will be shared with the following stakeholders:

• Drugs Controller General of India (DCGI).

• Concerned State or Union Territory Licensing Authority.

• Manufacturer of the concerned medicine.

• Marketer responsible for the drug's marketing and distribution.

This expanded reporting mechanism is expected to improve communication between regulatory authorities and pharmaceutical companies.

It will also help ensure that quality-related concerns reach the relevant stakeholders quickly, enabling faster investigation and regulatory intervention.

Amendments Follow Recommendations of DCC and DTAB

The proposed regulatory changes follow discussions and recommendations made during two important meetings involving India's drug regulatory bodies.

The matter was discussed at the 65th meeting of the Drugs Consultative Committee (DCC), held on December 20, 2024.

It was subsequently considered during the 92nd meeting of the Drugs Technical Advisory Board (DTAB) on April 24, 2025.

The recommendations from these meetings have contributed to the government's efforts to strengthen regulatory oversight and introduce more effective measures for dealing with substandard medicines.

Public Consultation Invited on Proposed Drug Rules

The Ministry of Health and Family Welfare has published the draft amendments for public consultation.

Stakeholders, pharmaceutical manufacturers, industry representatives and members of the public can submit their objections and suggestions within 30 days from the date on which copies of the Gazette notification are made available.

Where Can Stakeholders Submit Their Suggestions?

Interested individuals and organisations can send their feedback through the following channels:

Postal Address:

Under Secretary (Drugs),

Ministry of Health and Family Welfare,

Kartavya Bhawan-1, New Delhi.

Email: drugsdiv-mohfw@gov.in

The feedback received during the consultation process will help the government consider stakeholder concerns before finalising the proposed regulatory changes.

How Will the Proposed Amendments Benefit Patients?

The proposed changes are intended to make India's drug quality monitoring system more responsive and effective.

Immediate suspension powers could help authorities prevent continued manufacturing when medicines fail critical quality tests. Mandatory corrective measures would also encourage pharmaceutical companies to strengthen their internal quality management systems.

The revised reporting mechanism could further improve coordination between central and state regulators, manufacturers and marketers.

Overall, these measures are expected to strengthen post-marketing surveillance, improve pharmaceutical accountability and increase public confidence in the quality of medicines available in India.

Conclusion

The Centre's proposed amendments to the Drugs Rules, 1945, mark an important step towards strengthening India's pharmaceutical regulatory system. Immediate suspension of manufacturing licences, mandatory Root Cause Analysis and CAPA requirements could help prevent the production of substandard medicines. With improved reporting and regulatory coordination, the proposed framework aims to protect public health and ensure access to safe, effective and quality medicines.